The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by PR-Newswire.
NEW ORLEANS, Nov. 15, 2024 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until January 13, 2025 to file lead plaintiff applications in a securities class action lawsuit against PACS Group, Inc. (NYSE: PACS), if they purchased or otherwise acquired the Company's (a) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with the Company's April 2024 initial public offering ("IPO" or the "Offering"); and/or (b) securities between April 11, 2024 and November 5, 2024 inclusive (the "Class Period"). This action is pending in the United States District Court for the Southern District of New York.
RADNOR, Pa., Nov. 15, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against PACS Group, Inc. ("PACS") (NYSE: PACS). The lawsuit is brought on behalf of investors who purchased or otherwise acquired PACS: 1) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with PACS' April 11, 2024 initial public offering (the "IPO"); and/or 2) securities between April 11, 2024 and November 5, 2024 inclusive (the "Class Period"). The lead plaintiff deadline is January 13, 2025.
SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Robbins LLP announces that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired PACS Group, Inc. (NYSE: PACS) (a) common stock in connection with the Company's April 11, 2024 initial public offering ("IPO"), or (b) securities between April 11, 2024 and November 5, 2024. PACS Group, through its subsidiaries, operates senior care facilities, skilled nursing facilities, and assisted living facilities in the United States.
LOS ANGELES, Nov. 13, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PACS Group, Inc. ("PACS Group" or "the Company") (NYSE: PACS) for violations of the securities laws.
According to the Complaint, the Company made false and misleading statements to the market. PACS Group is the subject of a report issued by Hindenburg Research on November 4, 2024, titled: "PACS Group: How to Become A Billionaire In The Skilled Nursing Industry By Systematically Scamming Taxpayers." The report alleges that, "PACS abused a COVID-era waiver, inappropriately accessing skilled care Medicare benefits for thousands of patients across its national portfolio of facilities." Hindenburg further alleges that "the scheme drove more than 100% of PACS' operating and net income from 2020 - 2023, enabling PACS to IPO in early 2024 with the illusion of legitimate growth and profitability."
RADNOR, Pa., Nov. 9, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of PACS Group, Inc. (NYSE: PACS) ("PACS").
On November 4, 2024, Hindenburg Research published a report titled: "PACS Group: How to Become A Billionaire In The Skilled Nursing Industry By Systematically Scamming Taxpayers." Specifically, the report indicated after a 5-month investigation that included interviews with 18 former PACS employees, competitors, and an analysis of more than 900 PACS facility cost reports, Hindenburg found that "PACS abused a COVID-era waiver, inappropriately accessing skilled care Medicare benefits for thousands of patients across its national portfolio of facilities." Hindenburg further estimated that "the scheme drove more than 100% of PACS' operating and net income from 2020 - 2023, enabling PACS to IPO in early 2024 with the illusion of legitimate growth and profitability."
NEW YORK, Nov. 8, 2024 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of PACS Group, Inc. (NYSE: PACS) resulting from allegations that PACS Group may have issued materially misleading business information to the investing public.
So What: If you purchased PACS Group securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
LOS ANGELES, Nov. 8, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PACS Group, Inc. ("PACS Group" or "the Company") (NYSE: PACS) for violations of the securities laws.
According to the Complaint, the Company made false and misleading statements to the market. PACS Group is the subject of a report issued by Hindenburg Research on November 4, 2024, titled: "PACS Group: How to Become A Billionaire In The Skilled Nursing Industry By Systematically Scamming Taxpayers." The report alleges that, "PACS abused a COVID-era waiver, inappropriately accessing skilled care Medicare benefits for thousands of patients across its national portfolio of facilities." Hindenburg further alleges that "the scheme drove more than 100% of PACS' operating and net income from 2020 - 2023, enabling PACS to IPO in early 2024 with the illusion of legitimate growth and profitability."
SAN DIEGO, Nov. 5, 2024 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving PACS Group, Inc. (NYSE: PACS) focused on whether the company and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.
If you have information that could assist in the PACS Group Investigation or if you are a PACS Group investor who suffered a loss and would like to learn more, you can provide your information here: